GCM
BIIB icon

Glaxis Capital Management’s Biogen BIIB Stock Holding History

Glaxis Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-4,400
Closed -$1.06M – 36
2013
Q3 		$1.06M Buy
+4,400
New +$985K 2.13% 19

Other funds holding BIIB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Glaxis Capital Management's BIIB Position: Q4 2013 in Review

Glaxis Capital Management sold out of Biogen (BIIB) in Q4 2013, closing a stake of 4,400 shares — an estimated $1.06M sold.

Glaxis Capital Management first reported a position in BIIB in Q3 2013 and held it in 1 quarter. The position peaked at $1.06M in Q3 2013. 738 funds tracked by Wall St. Rank hold BIIB as of Q4 2013.

  • Glaxis Capital Management reported no remaining Biogen position as of Q4 2013 after selling out during the quarter.
  • Glaxis Capital Management sold 4,400 Biogen shares in Q4 2013, an estimated $1.06M.
  • Glaxis Capital Management first reported a position in Biogen in Q3 2013 and held it in 1 quarter.
  • Glaxis Capital Management's Biogen position peaked at $1.06M in Q3 2013.
  • 738 funds tracked by Wall St. Rank held Biogen as of Q4 2013.

Based on Glaxis Capital Management's 13F filing for Q4 2013, filed 5 Feb 2014.